Company: CERO
Filing Date: 2025-04-15
Form Type: 10-K
Source: 0001213900-25-032134
Chunk: 254

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-04-15
Form: 10-K
Item: Item 1
Chunk 254
---
 22, 2025. We continue to make progress towards satisfaction of the other conditions.
Nevertheless, as of the date of this Annual Report, the trading price of our Common Stock is below the Bid Price Requirement and we have
not satisfied the $2.5 million stockholder’s equity requirement. We cannot assure you that we will obtain compliance with these
requirements in a timely manner, or at all.

Nevertheless, if the Company
is unable to satisfy the Nasdaq Conditions, it is likely that the Company’s securities would be delisted. In addition, if we fail
to comply with the Bid Price Requirement at any time prior to the first anniversary of the Reverse Stock Split, we will be ineligible
for a 180-day compliance period during which we would otherwise be able to seek to regain compliance by soliciting stockholder approval
for another reverse stock split. Such a delisting would likely have a negative effect on the price of the securities and would impair
your ability to sell or purchase the securities when you wish to do so. In the event of a delisting, any action taken by us to restore
compliance with listing requirements may not allow our securities to become listed again, stabilize the market price or improve the liquidity
of our securities, prevent our securities from dropping below the Nasdaq minimum share price requirement or prevent future non-compliance
with Nasdaq’s listing requirements. Additionally, if our securities are not listed on, or become delisted from Nasdaq for any reason,
and are quoted on the over-the-counter bulletin board, an inter-dealer automated quotation system for equity securities that is not a
national securities exchange, the liquidity and price of our securities may be more limited than if we were quoted or listed on Nasdaq
or another national securities exchange.

If securities or industry analysts do not
publish research, or publish inaccurate or unfavorable research, about our business, our Common Stock share price and trading volume could
decline. 

The trading market for our
Common Stock will depend, in part, on the research and reports that securities or industry analysts publish about us or our business.
If few or no securities or industry analysts cover us, the trading price for our Common Stock would likely be negatively impacted. If
one or more of the analysts who cover us downgrade our Common Stock or publish inaccurate or unfavorable research about our business,
our share price would likely decline. In addition, if our operating results fail to meet the forecast of analysts, our share price would
likely decline. If one or more of